^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    GALEAS™ uPCR: ESR1

    Company:
    Nonacus
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    17d
    Nonacus introduces its first ultrasensitive qPCR assay for ESR1 mutation detection (Nonacus Press Release)
    "Nonacus Ltd, has launched GALEAS uPCR ESR1, an ultrasensitive qPCR (uPCR) assay developed to detect eleven mutations in the ESR1 gene which are known to be associated with resistance to endocrine therapy...The GALEAS uPCR ESR1 assay is a simple, affordable qPCR-based assay, developed for laboratories studying the role of ESR1 mutations in resistance to hormone therapy treatment."
    Launch
    |
    GALEAS™ uPCR: ESR1